|
AU2015201812A1
|
|
Methods for the treatment of cancer
|
|
US2014255436A1
|
|
Immunogenic compositions useful in provoking an integrated response to tumor antigens
|
|
US2011076232A1
|
|
Specific binding proteins and uses thereof
|
|
WO2010039248A1
|
|
Methods for the treatment of cancer
|
|
GB0820698D0
|
|
Uses of immunomodulators
|
|
WO2009039188A1
|
|
Peptides and methods for the treatment of gliomas and other cancers
|
|
WO2009023266A1
|
|
Generation of antibodies to cell-surface receptors and cancer-associated proteins including egfr family members
|
|
GB0806794D0
|
|
Therapeutic compounds
|
|
MX2009009782A
|
|
Treatment method using egfr antibodies and src inhibitors and related formulations.
|
|
EP2140247A1
|
|
Method for modulating activity of t lymphocytes
|
|
AU2008200559A1
|
|
VEGFR-3 Binding peptides and their use for inhibiting angiogenesis
|
|
GB0722274D0
|
|
New therapeutic method
|
|
WO2008042407A1
|
|
Melanoma repopulating cells
|
|
WO2008019366A2
|
|
Methods and compositions for increased priming of t-cells through cross-presentation of exogenous antigens
|
|
WO2008014458A2
|
|
Protein markers for the diagnosis and prognosis of ovarian and breast cancer
|
|
EP2021028A2
|
|
Methods and compositions for modulation of blood-neural barrier
|
|
EP1996614A1
|
|
Ctsp cancer-testis antigens
|
|
GB0701354D0
|
|
Adjuvants for dna vaccination
|
|
GB0701362D0
|
|
Adjuvants for DVA vaccination
|
|
WO2007111657A2
|
|
Method for diagnosing rheumatoid arthritis via assaying myofibroblast-like synoviocytes for fibroblast activation protein
|
